Skip to main content

Advertisement

SpringerLink
Log in

Pediatric inflammatory bowel disease

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

The combination of an unprecedented number of new therapeutic options (Fig. 1), along with new insights in how to optimize currently available therapies and advances in our understanding of disease pathogenesis, present many exciting new aspects to the management of patients with inflammatory bowel disease (IBD). Clinical management paradigms must evolve in parallel to keep pace with these advances. Traditional pediatric IBD regimens have underutilized combination therapies (Fig. 2) and immunomodulatory agents. Increased appreciation for steroid side effects is leading to a shift away from their inclusion in maintenance regimens. Immunomodulators are being introduced earlier in the course of disease for maintenance of remission and growth promotion. Recognition that the sole signs of active disease in children and adolescents may be growth and maturational delay, despite a relative lack of gastrointestinal symptoms, should prompt earlier, more aggressive interventions. When more potent, rapidly acting interventions such as infliximab, cyclosporine (CSA), or tacrolimus are considered, they should generally be co-administered with agents such as 6-mercaptopurine (6-MP) or azathioprine (AZA) for longer-term disease suppression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Burbige EJ, Huang SS, Bayless TM: Clinical manifestations of Crohn’s disease in children and adolescents. Pediatrics 1975, 55:866–871.

    PubMed  CAS  Google Scholar 

  2. Gryboski J, Hillemeier C: Inflammatory bowel disease in children. Med Clin North Am 1980, 64:1185–1202.

    PubMed  CAS  Google Scholar 

  3. Plevy SE, Taylor K, DeWoody KL, et al.: Tumor necrosis factor (TNF) microsatellite haplotypes and perinuclear anti-neutrophil cytoplasmic antibody (pANCA) identify Crohn’s disease patients with poor clinical responses to anti-TNF monoclonal antibody (cA2). Gastroenterology 1997, 112:A1062. This subanalysis of the infliximab trial reported by Targan et al. [66] suggests that stratification of CD patients based on serum immune and genetic markers may ultimately allow patients to be treated more selectively with specific cytokinedirected therapies.

    Google Scholar 

  4. Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, in press. The potential benefits of combining the patient’s TPMT genotype with thiopurine metabolite levels as a means of individualizing and optimizing 6-MP/AZA therapy are described in this study.

  5. Vasiliauskas EA: Monoclonal antibody therapy in inflammatory bowel disease. In Inflammatory Bowel Diseases: Nestlé Nutrition Workshop Series Clinical & Performance Programme. Edited by Bistrian BR, Walker-Smith JA. Nestec Ltd., Vevey/S. Karger AG, Basel; 1999, 2:237–255. This article reviews the rationale and role of cytokine specific monoclonal antibody therapies directed against TNF-a in the treatment of IBD and discusses specific considerations relevant to the application of this form of therapy in patient care.

  6. Kam L, Vasiliauskas EA, Landers CJ, et al.: Magnitude of response to Remicade correlates with marker antibody expression. Gastroenterology 1999, 116:A744(#G3232). This study suggests that responses to cytokine-specific interventions can be predicted based on pattern and magnitude of serum immune marker expression.

    Google Scholar 

  7. Rutgeerts P, Geboes K, Vantrappen G, et al.: Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990, 99:956–963.

    PubMed  CAS  Google Scholar 

  8. Hanauer SB: Inflammatory bowel disease. N Engl J Med 1996, 334:841–848. This is an excellent general overview of therapies used to treat IBD.

    Article  PubMed  CAS  Google Scholar 

  9. Sutherland LR, May GR, Shaffer EA: Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993, 118:540–549.

    PubMed  CAS  Google Scholar 

  10. Messori A, Brignola C, Trallori G, et al.: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: a meta-analysis. Am J Gastroenterol 1994, 89:692–698.

    PubMed  CAS  Google Scholar 

  11. Cohen MB, Seidman E, Winter H, et al.: Controversies in pediatric inflammatory bowel disease. Inflamm Bowel Dis 1998, 4:203–227. This conference summary highlights issues related to the care pediatric patients with IBD.

    Article  Google Scholar 

  12. Winter HS, Ng S: Consensus conference on the evaluation of drugs to treat children with inflammatory bowel disease. Inflamm Bowel Dis 1998, 4:101–131. These are the proceedings of a consensus conference held to evaluate issues regarding new and available therapies in IBD, and in particular, addresses issues specific to treating children and adolescents.

    Article  Google Scholar 

  13. Moody GA, Jayanthi V, Probert CS, et al.: Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996, 8:1179–1183.

    PubMed  CAS  Google Scholar 

  14. Pinczowski D, Ekbom A, Baron J, et al.: Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994, 107:117–120.

    PubMed  CAS  Google Scholar 

  15. Ferry GD, Kirschner BS, Grand RJ, et al.: Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gastroenterol Nutr 1993, 17:32–38.

    Article  PubMed  CAS  Google Scholar 

  16. Munkholm P, Langholz E, Davidsen M, et al.: Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994, 35:360–362.

    PubMed  CAS  Google Scholar 

  17. Sachar DB: Maintenance therapy in ulcerative colitis and Crohn’s disease. J Clin Gastroenterol 1995, 20:117–122.

    Article  PubMed  CAS  Google Scholar 

  18. Whittington PF, Barnes HV, Bayless TM: Medical management of Crohn’s disease in adolescence. Gastroenterology 1977, 72:1338–1344. This study describes how continued suppression of disease activity promotes growth.

    PubMed  CAS  Google Scholar 

  19. Kirschner BS: Ulcerative colitis and Crohn’s disease in children: diagnosis and management. Gastroenterol Clin North Am 1995, 24:99–117.

    PubMed  CAS  Google Scholar 

  20. Fernando del Rosario J, Orenstein SR, et al.: Retrospective analysis of alternate-day prednisone maintenance therapy for Crohn’s disease. Clin Pediatr 1998, 37:413–419.

    CAS  Google Scholar 

  21. Marx G, Seidman EG: Inflammatory bowel disease in pediatric patients. Curr Opin Gastroenterol 1999, 15:322–325.

    Article  PubMed  CAS  Google Scholar 

  22. Thomson ABR, Sadowski D, Jenkins R, et al.: Budesonide in the management of Crohn’s disease. Can J Gastroenterol 1997, 11:255–260.

    PubMed  CAS  Google Scholar 

  23. Present DH, Korelitz BI, Wisch N, et al.: Treatment of Crohn’s disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980, 302:981–987.

    Article  PubMed  CAS  Google Scholar 

  24. George J, Present DH, Pou R, et al.: The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996, 91:1711–1714.

    PubMed  CAS  Google Scholar 

  25. Bouhnik Y, Lemann M, Mary JY, et al.: Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996, 347:215–219.

    Article  PubMed  CAS  Google Scholar 

  26. Pearson DC, May GR, Fick GH, et al.: Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Ann Intern Med 1995, 123:132–142.

    PubMed  CAS  Google Scholar 

  27. Hawthorne AB, Logan RFA, Hawkey CJ, et al.: Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992, 305:20–22.

    PubMed  CAS  Google Scholar 

  28. Sandborn WJ: Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol 1998, 33(S225):92–99. This is comprehensive review of 6-MP and AZA and issues related to their use in IBD.

    Article  CAS  Google Scholar 

  29. Markowitz J, Rosa J, Grancher K, et al.: Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease. Gastroenterology 1990, 99:1347–1351.

    PubMed  CAS  Google Scholar 

  30. Verhave M, Winter HS, Grand RJ: Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990, 117:809–814.

    Article  PubMed  CAS  Google Scholar 

  31. Perrault J, Greseth JLM, Tremaine WJ: 6-mercaptopurine therapy in selected cases of corticosteroiddependent Crohn’s disease. Mayo Clin Proc 1991, 66:480–484.

    PubMed  CAS  Google Scholar 

  32. Markowitz J, Grancher K, Mandel F, et al.: Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Am J Gastroenterol 1993, 88:44–48. This report summarizes the results of a survey of pediatric gastroenterologists’ attitudes toward the use of immunosuppressive agents in the treatment of children with IBD and highlights the cumulative pediatric experience with 6-MP and AZA.

    PubMed  CAS  Google Scholar 

  33. Kader HA, Mascarenhas MR, Piccoli DA, et al.: Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999, 28:54–58.

    Article  PubMed  CAS  Google Scholar 

  34. Kirschner BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998, 115:813–821.

    Article  PubMed  CAS  Google Scholar 

  35. Connell WR, Kamm MA, Dickson M, et al.: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994, 343:1249–1252.

    Article  PubMed  CAS  Google Scholar 

  36. Kim PS, Zlatanic J, Korelitz BI, et al.: Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease. Am J Gastroenterol 1999, 94:3254–3257.

    Article  PubMed  CAS  Google Scholar 

  37. Sandborn WJ, Tremaine WJ, Wolf DC, et al.: Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. Gastroenterology 1999, 117, 527–535.

    Article  PubMed  CAS  Google Scholar 

  38. Dubinsky M, Hassard P, Yang HY, et al.: 6-MP metabolite levels correlate with clinical response and drug toxicity in adult IBD. Am J Gastroenterol 1999, 94:2641(#A258).

    Google Scholar 

  39. Dubinsky M, Hassard P, Seidman EG, et al.: Serial 6-MP metabolite measurements identify 6-MP resistant IBD patients. Am J Gastroenterol 1999, 94:2641(#A259).

    Google Scholar 

  40. Feagan BG, Rochon J, Fedorak RN, et al.: Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995, 332:292–297.

    Article  PubMed  CAS  Google Scholar 

  41. Egan LJ, Sandborn WJ: Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996, 71:69–80. This is a superb summary of the pharmacology of MTx and its use in IBD.

    Article  PubMed  CAS  Google Scholar 

  42. Lemann M, Chamiot-Prieur C, Mesnard B, et al.: Methotrexate for the treatment of refractory Crohn’s disease. Aliment Pharmacol Ther 1996, 10:309–314.

    Article  PubMed  CAS  Google Scholar 

  43. Mack DR, Young R, Kaufman SS, et al.: Methotrexate in patients with Crohn’s disease after 6-mercaptopurine. Pediatrics 1998, 132:830–835.

    Article  CAS  Google Scholar 

  44. Deslandres C: Methotrexate: an alternative treatment in pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 1999, 29:520(#A125).

    Article  Google Scholar 

  45. Fickert P, Hinterleitner TA, Wenzl HH, et al.: Mycophenolate mofetil in patients with Crohn’s disease. Am J Gastroenterol 1998, 93:2529–2532.

    Article  PubMed  CAS  Google Scholar 

  46. Neurath MF, Wanitschke R, Peters M, et al.: Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 1999, 44:625–628.

    Article  PubMed  CAS  Google Scholar 

  47. Hassard PV, Vasiliauskas EA, Kam LY, et al.: Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn’s disease. Inflamm Bowel Dis 2000, in press.

  48. Gershman G, Ament ME: Mycophenolate mofetil (MMF) induces remission in refractory pediatric patients with IBD. J Pediatr Gastroenterol Nutr 1999, 29:521(#A127).

    Article  Google Scholar 

  49. Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841–1845.

    Article  PubMed  CAS  Google Scholar 

  50. Actis GC, Ottobrelli A, Pera A, et al.: Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol 1993, 17:10–13.

    Article  PubMed  CAS  Google Scholar 

  51. Abreu-Martin MT, Vasiliauskas EA, Gaiennie J, et al.: Continuous infusion cyclosporine (CSA) is effective for severe acute Crohn’s disease (CD) but for how long? Gastroenterology 1996, 110:A851.

    Google Scholar 

  52. Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995, 1:48–63. This review summarizes the published literature and critically examines the role of CSA in the management of IBD.

    Article  Google Scholar 

  53. Hanauer SB, Smith MB: Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993, 88:646–649.

    PubMed  CAS  Google Scholar 

  54. Present DH, Lichtiger S: Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci 1994, 39:374–380.

    Article  PubMed  CAS  Google Scholar 

  55. Brynskov J, Freund L, Rasmussen SN, et al.: A placebocontrolled, double-blind randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N Engl J Med 1989, 321:845–850.

    Article  PubMed  CAS  Google Scholar 

  56. Feagan BG, McDonald JWD, Rochon J, et al.: Low-dose cyclosporine for the treatment of Crohn’s disease. N Engl J Med 1994, 330:1846–1851.

    Article  PubMed  CAS  Google Scholar 

  57. Treem WR, Cohen J, Davis PM, et al.: Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum 1995, 38:474–479.

    Article  PubMed  CAS  Google Scholar 

  58. Oppong K, Record CO: Neoral may be as effective as intravenous cyclosporine in the treatment of steroidresistant ulcerative colitis. Am J Gastroenterol 1998, 93:1188–1189.

    Article  PubMed  CAS  Google Scholar 

  59. Sandborn WJ: Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Am J Gastroenterol 1997, 92:876–879.

    PubMed  CAS  Google Scholar 

  60. Lowry PW, Weaver AL, Tremaine WJ, et al.: Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatmentrefractory Crohn’s disease perianal fistulae. Inflamm Bowel Dis 1999, 5:239–245.

    Article  PubMed  CAS  Google Scholar 

  61. Bousvaros A, Kirschner B, Werlin S, et al.: Oral tacrolimus treatment of severe colitis in children: long-term follow-up. J Pediatr Gastroenterol Nutr 1998, 27:463(#A2).

    Article  Google Scholar 

  62. Fellermann K, Ludwig D, Stahl M, et al.: Steroidunresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998, 93:1860–1866.

    Article  PubMed  CAS  Google Scholar 

  63. Sands BE, Podolsky DK, Tremaine WJ, et al.: Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis (UC). Gastroenterology 1996, 110:A1008.

    Article  Google Scholar 

  64. Derkx B, Taminiau J, Radema S, et al.: Tumour-necrosisfactor antibody treatment in Crohn’s disease. Lancet 1993, 342:173–174.

    Article  PubMed  CAS  Google Scholar 

  65. Van Dullemen HM, van Deventer SJH, Hommes DW, et al.: Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129–135.

    Article  PubMed  Google Scholar 

  66. Targan SR, Hanauer SB, van Deventer SJH, et al.: A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease. N Engl J Med 1997, 337:1029–1035.

    Article  PubMed  CAS  Google Scholar 

  67. Stack WA, Mann SD, Roy AJ, et al.: Randomised controlled trial of CDP571 antibody to tumour necrosis factor a in Crohn’s disease. Lancet 1997, 349:521–524.

    Article  PubMed  CAS  Google Scholar 

  68. Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999, 340:1398–1405.

    Article  PubMed  CAS  Google Scholar 

  69. Rutgeerts P, D’Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999, 117:761–769.

    Article  PubMed  CAS  Google Scholar 

  70. Vasiliauskas EA, Thomas DW, Schaffer S, et al.: Collaborative experience of open-label infliximab, in refractory pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 1999, 29:525(#A144).

    Article  Google Scholar 

  71. Hadigan C, Baldassano R, Braegger CP, et al.: Pharmacokinetics of infliximab (anti-TNFa) in children with Crohn’s disease: a multicenter trail. J Pediatr Gastroenterol Nutr 1999, 29:525(#A143).

    Article  Google Scholar 

  72. Elliott MJ, Maini RN, Feldmann M, et al.: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994, 344:1125–1127.

    Article  PubMed  CAS  Google Scholar 

  73. Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999, 5:119–133. This paper reviews issues related to the use of the anti-TNFa agents infliximab, CDP571, and etanercept in IBD.

    Article  PubMed  CAS  Google Scholar 

  74. Remicade product information. Physicians Desk Reference. Montvale, NJ: Medical Economics Company, Inc., 2000, 54th ed.:927–930.

    Google Scholar 

  75. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al.: An open-label pilot study of low-dose thalidomide in chronically-active, steroid-dependent Crohn’s disease. Gastroenterology 1999, 117:1278–1287.

    Article  PubMed  CAS  Google Scholar 

  76. Wettstein AR, Meagher AP: Thalidomide in Crohn’s disease. Lancet 1997, 350:1445–1446.

    Article  PubMed  CAS  Google Scholar 

  77. Ehrenpreis ED, Kane SV, Cohen LB, et al.: Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial. Gastroenterology 1999, 117:1271–1277.

    Article  PubMed  CAS  Google Scholar 

  78. Odeka EB, Miller V: Thalidomide in oral Crohn’s disease refractory to conventional medical treatment. J Pediatr Gastroenterol Nutr 1997, 25:250–251.

    Article  Google Scholar 

  79. Weinstein TA, Sciubba JJ, Levine J: Thalidomide for the treatment of oral aphthous ulcers in Crohn’s disease. J Pediatr Gastroenterol Nutr 1999, 28:214–216.

    Article  PubMed  CAS  Google Scholar 

  80. Belluzzi A, Brignola C, Campieri M, et al.: Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med 1996, 334:1557–1560.

    Article  PubMed  CAS  Google Scholar 

  81. Sandborn WJ: Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Am J Gastroenterol 1999, 94:1161–1171.

    Article  PubMed  CAS  Google Scholar 

  82. Burakoff R: Less commonly used therapies for IBD or treatments on the fringe. Proceedings of the Inflammatory Bowel Disease Workshop held in Vail, Colorado, March 22 and 23, 1998. Inflamm Bowel Dis 1998, 4:308–317. The roles of nicotine, fish oil, short-chain fatty acids, hydroxychloroquine, antibiotics, and enteral nutrition as a primary therapy in IBD are reviewed and discussed.

    Article  PubMed  CAS  Google Scholar 

  83. van Deventer SJ, Elson CO, Fedorak RN: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 1997, 113:383–389.

    Article  PubMed  Google Scholar 

  84. Motil KJ, Grand RJ: Nutritional management of inflammatory bowel disease. Pediatr Clin N Am 1985, 32:447–469.

    CAS  Google Scholar 

  85. Seidman E, LeLeiko N, Ament M, et al.: Nutritional issues in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991, 12:424–438.

    Article  PubMed  CAS  Google Scholar 

  86. Calam J, Crooks PE, Walker RJ: Elemental diets in the management of Crohn’s perianal fistulae. J Parenter Enter Nutr 1980, 4:4–8.

    Article  CAS  Google Scholar 

  87. Teahon K, Bjarnason I, Pearson M, et al.: Ten years experience with an elemental diet in the management of Crohn’s disease. Gut 1990, 31:1133–1137.

    PubMed  CAS  Google Scholar 

  88. Lavy A, Weisz G, Adir Y, et al.: Hyperbaric oxygen for perianal Crohn’s disease. J Clin Gastroenterology 1994, 19:202–205.

    Article  CAS  Google Scholar 

  89. Gryboski JD: Crohn’s disease in children 10 years old and younger: comparison with ulcerative colitis. J Pediatr Gastroenterol Nutr 1994, 18:174–182.

    Article  PubMed  CAS  Google Scholar 

  90. Motil KJ, Grand RJ, Davis-Kraft L, et al.: Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993, 105:681–691.

    PubMed  CAS  Google Scholar 

  91. Kanof ME, Lake AM, Bayless TM: Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology 1988, 95:1523–1527.

    PubMed  CAS  Google Scholar 

  92. Markowitz J, Grancher K, Rosa J, et al.: Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993, 16:373–380.

    Article  PubMed  CAS  Google Scholar 

  93. Griffiths AM, Nguyen P, Smith C, et al.: Growth and clinical course of children with Crohn’s disease. Gut 1993, 34:939–943.

    PubMed  CAS  Google Scholar 

  94. Homer DR, Grand RJ, Colodny AH: Growth, course, and prognosis after surgery for Crohn’s disease in children and adolescents. Pediatrics 1977, 59:717–725. This is a retrospective analysis of postoperative outcomes of children with CD as measured by growth patterns following surgery.

    PubMed  CAS  Google Scholar 

  95. McLain BI, Davidson PM, Stokes KB, et al.: Growth after gut resection for Crohn’s disease. Arch Dis Child 1990, 65:760–762. This study examines the effect surgical resection of diseased bowel on subsequent growth in children with CD.

    PubMed  CAS  Google Scholar 

  96. Gokhale R, Favus MJ, Karrison T, et al.: Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998, 114:902–911.

    Article  PubMed  CAS  Google Scholar 

  97. Van Citters G, Lin HC: Oleic acid improves drug absorption in patients with inflammatory bowel disease. Gastroenterology 1998, 114:A1105(#G4521).

    Google Scholar 

  98. Bayless TM, Harris ML: Inflammatory bowel disease and irritable bowel syndrome. Med Clin North Am 1990, 74:21–28.

    PubMed  CAS  Google Scholar 

  99. Pimentel M, Lin HC: Eradication of small intestinal bacterial overgrowth decreases symptoms in Crohn’s Disease. Am J Gastroenterol 1999, 94:2647(#A282). This study suggests that recognition and treatment of small intestinal bacterial overgrowth eliminates or reduces symptoms that might otherwise be attributed to a flare of CD.

    Google Scholar 

  100. Thomas AO, Rhodes J, Green JT: Inflammatory bowel disease and smoking-a review. Am J Gastroenterol 1998, 93:144–149.

    PubMed  CAS  Google Scholar 

  101. Bjarnason I, Price AB, Zanelli G, et al.: Clinicopathological features of nonsteroidal antiinflammatory druginduced small intestinal strictures. Gastroenterology 1988, 94:1070–1074.

    PubMed  CAS  Google Scholar 

  102. Facklis K, Plevy SE, Vasiliauskas EA, et al.: Crohn’s disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications. Dis Colon Rectum 1999, 42:601–606.

    Article  PubMed  CAS  Google Scholar 

  103. Fleshner PR, Vasiliauskas EA, Kam L, et al.: High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch anal anastomosis. Gastroenterology 1999, 116:A716(#G3107).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, 8631 West Third St., Suite 430E, 90048, Los Angeles, CA, USA

    Eric Vasiliauskas MD

Authors
  1. Eric Vasiliauskas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vasiliauskas, E. Pediatric inflammatory bowel disease. Curr Treat Options Gastro 3, 403–424 (2000). https://doi.org/10.1007/s11938-000-0055-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-000-0055-2

Keywords

Search

Navigation